Guide to German Biotech Companies 2025 - Blick ins Buch

26

th

2025 In cooperation with: BPI German Pharmaceutical Industry Association DECHEMA Society for Chemical Engineering and Biotechnology European Biotechnology Network VDGH German Diagnostics Industry Association

ISBN 978-3-928383-93-6

26th Guide to German Biotech Companies 2025

Content

Editorial . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

3

The German Biotech Sector 2024 . .

7

Prefaces of Biotech Associations Dr Kai Joachimsen, BPI e.V. . . . . . . . . . . . . . . . . .

Dr Kathrin Rübberdt, DECHEMA e.V. . . . . . . . . . .

Dr Martin Walger, VDGH e.V. . . . . . . . . . . . . . . . . .

Profiles of German Biotech Companies. . . . . . . .

4base lab AG . . . . . . . . . . . . . . . . . . . . . . . . . . . .

AGC Biologics GmbH . . . . . . . . . . . . . . . . . . . . . . anwerina Deutschland GmbH . . . . . . . . . . . . . . . .

AvenCell Europe GmbH . . . . . . . . . . . . . . . . . . . .

Axolabs GmbH . . . . . . . . . . . . . . . . . . . . . . . . . . .

B4 PharmaTech GmbH . . . . . . . . . . . . . . . . . . . . .

Biaffin GmbH & Co KG . . . . . . . . . . . . . . . . . . . . .

Bio-Techne GmbH . . . . . . . . . . . . . . . . . . . . . . . .

BioCopy AG . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Boehringer Ingelheim Biopharmaceuticals GmbH .

BRAIN Biotech AG . . . . . . . . . . . . . . . . . . . . . . . .

CeGaT GmbH . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Cellex Cell Professionals . . . . . . . . . . . . . . . . . . .

CG Chemikalien GmbH & Co. KG . . . . . . . . . . . . .

Coriolis Pharma Research GmbH . . . . . . . . . . . . .

CureVac AG . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Dynamic42 GmbH . . . . . . . . . . . . . . . . . . . . . . . .

EVONIK Operations GmbH . . . . . . . . . . . . . . . . . .

EW Biotech GmbH . . . . . . . . . . . . . . . . . . . . . . . .

FGK Clinical Research GmbH . . . . . . . . . . . . . . .

Fraunhofer ITEM. . . . . . . . . . . . . . . . . . . . . . . . . .

GALAB Laboratories GmbH . . . . . . . . . . . . . . . . . glyXera GmbH . . . . . . . . . . . . . . . . . . . . . . . . . . .

Heidelberg Pharma AG . . . . . . . . . . . . . . . . . . . . .

IBA Lifesciences GmbH . . . . . . . . . . . . . . . . . . . .

Immunic AG . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Indivumed GmbH . . . . . . . . . . . . . . . . . . . . . . . . . innoME GmbH . . . . . . . . . . . . . . . . . . . . . . . . . . .

InVivo BioTech Services GmbH . . . . . . . . . . . . . . iOmx Therapeutics AG . . . . . . . . . . . . . . . . . . . . .

ITM Isotope Technologies Munich SE . . . . . . . . .

Kosmas Therapeutics GmbH . . . . . . . . . . . . . . . .

16 18 20

23 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52 54 56 58 60 62 64 66 68 70 72 74 76 78 80 82 84 86

KyooBe Tech GmbH . . . . . . . . . . . . . . . . . . . . . . . 88 Lonza Cologne GmbH . . . . . . . . . . . . . . . . . . . . . 90 metabion international AG . . . . . . . . . . . . . . . . . . 92 Mettler-Toledo GmbH . . . . . . . . . . . . . . . . . . . . . . 94 Microcoat Biotechnologie GmbH . . . . . . . . . . . . . 96 Microsynth Seqlab GmbH . . . . . . . . . . . . . . . . . . 98 Miltenyi Biotec B.V. & Co. KG . . . . . . . . . . . . . . . . 100 Molzym GmbH & Co.KG . . . . . . . . . . . . . . . . . . . . 102 MucosaTec GmbH . . . . . . . . . . . . . . . . . . . . . . . . 104 Navigo Proteins GmbH . . . . . . . . . . . . . . . . . . . . . 106 Neovii Biotech GmbH . . . . . . . . . . . . . . . . . . . . . . 108 New England Biolabs GmbH . . . . . . . . . . . . . . . . 110 NIPPON Genetics EUROPE GmbH . . . . . . . . . . . 112 Nordmark Pharma GmbH . . . . . . . . . . . . . . . . . . . 114 Nova Biomedical GmbH . . . . . . . . . . . . . . . . . . . . 116 Omicron-Laserage® Laserprodukte GmbH . . . . . 118 PAN-Biotech GmbH . . . . . . . . . . . . . . . . . . . . . . . 120 Pantherna Therapeutics GmbH . . . . . . . . . . . . . . 122 PELOBiotech GmbH . . . . . . . . . . . . . . . . . . . . . . . 124 PharmaLex GmbH . . . . . . . . . . . . . . . . . . . . . . . . 126 Pharmaplan GmbH . . . . . . . . . . . . . . . . . . . . . . . . 128 Phyton Biotech GmbH . . . . . . . . . . . . . . . . . . . . . 130 PlasmidFactory GmbH . . . . . . . . . . . . . . . . . . . . . 132 ProBioGen AG . . . . . . . . . . . . . . . . . . . . . . . . . . . 134 Process Sensing Technologies PST GmbH . . . . . 136 PROGEN Biotechnik GmbH . . . . . . . . . . . . . . . . . 138 ProJect Pharmaceutics GmbH . . . . . . . . . . . . . . . 140 ProtaGene GmbH . . . . . . . . . . . . . . . . . . . . . . . . . 142 PSL Peptide Specialty Laboratories GmbH . . . . . 144 ReliaTech GmbH . . . . . . . . . . . . . . . . . . . . . . . . . . 146 Rentschler Biopharma SE . . . . . . . . . . . . . . . . . . . 148 Richter-Helm BioLogics GmbH & Co. KG . . . . . . . 150 Roche Diagnostics GmbH . . . . . . . . . . . . . . . . . . 152 ScheBo® · Biotech AG . . . . . . . . . . . . . . . . . . . . . 154 SciRhom GmbH . . . . . . . . . . . . . . . . . . . . . . . . . . 156 SERVA Electrophoresis GmbH . . . . . . . . . . . . . . . 158 SGS Analytics Germany GmbH . . . . . . . . . . . . . . 160 Sino Biological Europe GmbH . . . . . . . . . . . . . . . 162 Sirius Fine Chemicals SiChem GmbH . . . . . . . . . 164 SPT LABTECH LTD . . . . . . . . . . . . . . . . . . . . . . . . 166 Tebubio GmbH . . . . . . . . . . . . . . . . . . . . . . . . . . . 168 Tosoh Bioscience GmbH . . . . . . . . . . . . . . . . . . . 170 TRIGA-S Scientific Solutions . . . . . . . . . . . . . . . . 172 Valicare GmbH . . . . . . . . . . . . . . . . . . . . . . . . . . . 174

Vetter Pharma International GmbH . . . . . . . . . . . . 176 Vivoryon Therapeutics N.V. . . . . . . . . . . . . . . . . . . 178 WuXi Biologics Germany GmbH . . . . . . . . . . . . . . 180 X-act Cologne Clinical Research GmbH . . . . . . . . 182 YMC Europe GmbH. . . . . . . . . . . . . . . . . . . . . . . . 184 YUMAB GmbH . . . . . . . . . . . . . . . . . . . . . . . . . . . 186

Profiles of Service Providers . . . . . . . . . 188 BIO.NRW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 190 BIOCOM Interrelations GmbH . . . . . . . . . . . . . . . 192 BioM Biotech Cluster Development GmbH . . . . . 194 biomindz Standortentwicklungsgesellschaft Mainz mbH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 196 btS e.V . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 198 Dr. Ebeling & Assoc. GmbH . . . . . . . . . . . . . . . . . 200 HealthCapital – Cluster Healthcare Industries Berlin-Brandenburg . . . . . . . . . . . . . . . . . . . . . . . 202 HOX Life Science GmbH . . . . . . . . . . . . . . . . . . . 204 iQ spaces Management GmbH . . . . . . . . . . . . . . 206 IZB Martinsried . . . . . . . . . . . . . . . . . . . . . . . . . . . 208 Life Science Nord Management GmbH . . . . . . . . 210 LUMIS International GmbH . . . . . . . . . . . . . . . . . 212 Meissner Bolte Patentanwälte Rechtsanwälte Partnerschaft mbB . . . . . . . . . . . . . . . . . . . . . . . . 214 Osborne Clarke. . . . . . . . . . . . . . . . . . . . . . . . . . . 216 restracon GmbH & Co. KG . . . . . . . . . . . . . . . . . . 218 Rock Capital Group | Rock Capital Investment GmbH . . . . . . . . . . . . . . 220 SaxoCell . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 222 Technologiepark Weinberg Campus . . . . . . . . . . . 224 VON ROHR Patentanwälte Partnerschaft mbB . . 226 Wirtschaftsförderung Sachsen GmbH . . . . . . . . . 228 Wuesthoff & Wuesthoff Patentanwälte PartG mbB . . . . . . . . . . . . . . . . . . 230 German Biotech Companies . . . . . . . . . 232 Advertisements BIOCOM European Biotechnology Magazine. . . .

6 eurobiotechjobs.net . . . . . . . . . . . . . . . . . . . . . . . 22 BIOCOM |transkript. . . . . . . . . . . . . . . . . . . . . . . . 188 26 TH GUIDE TO GERMAN BIOTECH COMPANIES 2025

4|5

Engage with customers all over Europe Europe is a common research area and, for the industry, it represents a huge unified market with more than 500 million potential customers. The magazine European Biotechnology has been both monitoring and shaping this economic area for 23 years now. Together, we can keep improving. Join us!

Annual subscription €80 Please order online: european-biotechnology.com

european-biotechnology.com BIOCOM Interrelations GmbH I Jacobsenweg 61 I 13509 Berlin I Germany Tel. +49 (0)30 264921-54 | info@biocom.de I www.biocom.de

The German Biotechnology Sector 2024

On the one hand, on the other. Is good good enough?

These are the thoughts that come to mind when looking at the latest OECD data on the development of the German biotechnology sector. On the one hand, the German economy was in a phase of stagnation last year - even a technology of the future finds it difficult to compete against the leaden mood of late. Significant growth therefore appears to be a particular success.

On the other hand, the biotechnology sector is developing solutions to two of today’s megaproblems: climate change and the ageing of societies in industrialised countries. Anyone who jumps on this bandwagon has the chance of exponential growth - something that has not happened again in 2023.

And the role of biotechnology is also becoming increasingly clear in other areas, such as feeding a growing world population: CRISPR/Cas and precision fermentation are the current growth drivers. In the field of sustainable materials, biotechnology applications offer innovative and climate-friendly solutions, as do new recycling technologies for the circular economy.

Not only has investment in research and development increased significantly, but a large number of new employees have also been hired, despite the prevailing shortage of skilled labour. It is also pleasing to note that a number of new companies have been set up despite the poor general economic climate. All of this testifies to the industry’s strong self-confidence and enthusiasm for innovation.

After the growth spurt in the early 2020s due to the novel mRNA vaccines against the coronavirus pandemic, industry figures normalised in 2023 - only revenues continued to fall significantly due to the lack of vaccine sales. By contrast, expenditure on research and development rose to a new record high. Companies invested a total of €3.74 billion, with almost €3.4 billion going into the research of new compounds, technologies and products or the further development of existing healthcare projects.

These assessments are confirmed by the results of BIOCOM’s Biotechnology Company Survey 2024, which analysed the key figures for 2023 in the spring.

BIOCOM has been analysing the development of the biotechnology sector in Europe for 38 years. Since 2005, the annual survey of German biotechnology companies has been internationally comparable according to the criteria of the Organisation for Eco-

Key figures of the biotech sector in Germany 2015

2016

2017

2018

2020

2021

2022

2023

Number of dedicated biotechnology companies

593

615

646

679

736

753

776

798

Number of employees in dedicated companies

19,010

20,280

21,860

23,540

27,200

30,280

34,390

38,120

Turnover of dedicated biotechnology companies

€3.28bn €3.54bn €4.11bn €4.51bn €6.71bn €26.5bn €25.4bn €12.57bn

R&D expenditures of dedicated biotechnology companies

€1.04bn €1.10bn €1.12bn €1.19bn €2.14bn €2.83bn €3.33bn €3.74bn

26 TH GUIDE TO GERMAN BIOTECH COMPANIES 2025

6|7

Name › 4base lab AG advanced molecular analysis Address/P.O. Box › Aspenhaustr. 25 Postal Code/City › 72770 Reutlingen State › Baden-Wuerttemberg Contact Person › Dr Johannes Ries Telephone › +49-7121-317878-0 Email › pharma@4base-lab.com Website › https://en.4base-lab.com/pharma/ Founded (year) › 1995 Type of Laboratory › GMP, S1/L2 Areas of Activity › | Identity/quality assessment of mRNA/ DNA vaccines | Contamination analysis of residual DNA/RNA | Vaccine quality analysis by Nanopore direct RNA-sequencing | DNA/cDNA-sequencing by Sanger | Determination of mRNA poly(A) tail length | Sequencing the CDS in mRNA | Direct colony full-length sequencing | Contract research/outsourcing | Viral- and microbial detection

The Experts For almost three decades, 4base lab has been at the forefront of molecular analysis, maintaining GMP-compliant laboratories that consistently meet the highest industry standards. As a reliable partner of mRNA/DNA vaccine manufacturers including leading pharmaceutical companies, 4base lab offers safety at every stage of the manufacturing process.

Excellence through collaboration is our guiding principle. Our team of experienced scientists and qualified technicians partners closely with you to comprehend your unique objectives. We leverage this understanding to develop customized assays and validation methods that are tailored to your specific requirements and ensure optimal results.

Customized advice and flexible adaptation of our test systems are our strengths.

The services DNA sequencing: The confirmation of sequence identity is an essential part of the production of therapeutic nucleic acids. 4base lab offers reliable non-GMP and GMP sequencing services according to Sanger, covering all steps necessary for the determination of complete DNA sequences. Even samples with ultra-low DNA concentrations, limited volume or colonies can be sequenced in full-length using validated Rolling Circle Amplification (RCA) methods.

RNA sequencing: The assessment of therapeutic mRNA vaccines directly, without reliance on intermediate molecules, is increasingly in focus of regulatory quality control requirements regarding the sequence coding identity, modifications, and structural motifs. 4base lab offers a qualified analysis pipeline to address these issues directly on the RNA.

4BASE L AB

Determination of poly(A) tail length: for determination of poly(A) length of mRNA vaccines, qualified sequencing strategies utilizing Sanger adapter sequencing as well as Oxford Nanopore Technologies (ONT) direct RNA sequencing are available.

Residual nucleic acid analysis: Detection of residual DNA contamination. Safety at every step of your manufacturing process of mRNA vaccines. Various validated qPCR/RT-PCR protocols are established for the detection of residual E. coli genomic DNA, RNA and plasmid DNA contaminant in mRNA vaccines.

Development and Validation: New detection systems can be developed at any time according to customer requirements and validated in accordance with ICH Q2.

Viral and microbial detection: Please inquire for available systems.

Quality assurance 4base lab has been maintaining GMP compliant laboratories for m ­ olecular analysis for almost three decades.

Furthermore, 4base lab is certified according to DIN EN ISO 9001, DIN EN ISO 14001 and accredited according to DIN EN ISO 17025.

26 TH GUIDE TO GERMAN BIOTECH COMPANIES 2025

24 | 25